Order Article Reprints

Shah MA, Udrea AA, Bondarenko I, Mansoor W, Sánchez RG, Sarosiek T, Bozzarelli S, Schenker M, Gomez-Martin C, Morgan C, et al. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers. 2022; 14(5):1168. https://doi.org/10.3390/cancers14051168

Shah, Manish A., Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeño Sánchez, Tomasz Sarosiek, Silvia Bozzarelli, Michael Schenker, Carlos Gomez-Martin, Carys Morgan, and et al. 2022. "Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies" Cancers 14, no. 5: 1168. https://doi.org/10.3390/cancers14051168

Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., Sánchez, R. G., Sarosiek, T., Bozzarelli, S., Schenker, M., Gomez-Martin, C., Morgan, C., Özgüroğlu, M., Pikiel, J., Kalofonos, H. P., Wojcik, E., Buchler, T., Swinson, D., Cicin, I., Joseph, M., Vynnychenko, I., ... Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 14(5), 1168. https://doi.org/10.3390/cancers14051168